Organovo (NASDAQ:ONVO – Get Free Report) released its quarterly earnings data on Wednesday. The medical research company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02, Zacks reports. Organovo had a negative net margin of 12,176.70% and a negative return on equity of 249.28%.
Organovo Stock Performance
NASDAQ ONVO traded up $0.01 on Wednesday, reaching $0.40. The company had a trading volume of 30,464 shares, compared to its average volume of 159,223. The firm has a market capitalization of $6.07 million, a price-to-earnings ratio of -0.37 and a beta of 0.54. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74. The company’s fifty day moving average is $0.38 and its 200-day moving average is $0.45.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on shares of Organovo in a research note on Saturday. They issued a “sell” rating for the company.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Stories
- Five stocks we like better than Organovo
- 10 Best Airline Stocks to Buy
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- Best Stocks Under $10.00
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- How to Start Investing in Real Estate
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
